Frequent Genetic Alterations in Metastatic Prostate Cancer Revealed by Targeted Sequencing
Journal of Urologic Oncology · 31.07.2026 · 24 (2) · 101-108
DOI: 10.22465/juo.255000700035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Urologic Oncology, erschienen am 31.07.2026. Verfasst von Seung-Hwan Jeong und 5 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Education, Seoul National University Hospital.
Abstract (Originalsprache)
Purpose
This study used the Seoul National University Hospital FIRST-Cancer Panel (v3.2.2) to identify potentially druggable targets in prostate cancer. We compared genetic alterations between primary, treatmentnaive, hormone-sensitive prostate cancer (HSPC) tissue obtained at initial diagnosis and metastatic, castrationresistant prostate cancer (CRPC) tissue obtained after disease recurrence to identify candidate genes associated with the metastatic, castration-resistant phenotype. Because this was a cross-sectional comparison, the findings represent associations only and do not establish a causal role in metastasis.Materials and Methods: We analyzed samples from 93 patients with prostate cancer using the FIRST-Cancer Panel, which included 192 genes, 25 fusion genes, 8 microsatellite instability markers, and 45 druggable genomic targets. The cohort comprised 80 primary, treatment-naive HSPC tumor samples obtained at diagnosis and 13 distant metastatic CRPC samples obtained after recurrence. DNA was extracted from formalin-fixed paraffin-embedded tissue, sequenced using the NextSeq 550Dx platform, and analyzed with the Seoul National University Hospital CPM Solid v3.7 pipeline. Oncoprint analysis using cBioPortal and survival analyses were performed to assess clinical implications, and GraphPad Prism was used for correlation analysis.
Results
Patient age, microsatellite instability status, and tumor mutational burden were comparable between the groups, but oncoprint analysis showed distinct alteration patterns. Primary tumors most frequently showed alterations in FOXA1, RB1, BRCA2, TP53, and SPOP, whereas metastatic samples most frequently showed alterations in FANCA, TMPRSS2, ERG, PTEN, and TP53, consistent with previous reports implicating these genes in advanced prostate cancer. In this exploratory comparison, UGT1A1, NOTCH3, and MAP3K4 were altered more frequently in metastatic samples than in primary samples. In external, aggregated cBioPortal cohorts, UGT1A1 and NOTCH3 alterations were associated with poorer 5-year overall survival rates (
Förderung
- National Research Foundation of Korea
- Ministry of Education
- Seoul National University Hospital
Zitieren
APA
Jeong, S., Han, J. H., Yuk, H. D., Jeong, C. W., Ku, J. H., & Kwak, C. (2026). Frequent Genetic Alterations in Metastatic Prostate Cancer Revealed by Targeted Sequencing. Journal of Urologic Oncology, 24(2), 101-108. https://doi.org/10.22465/juo.255000700035
Vancouver
Jeong S, Han JH, Yuk HD, Jeong CW, Ku JH, Kwak C. Frequent Genetic Alterations in Metastatic Prostate Cancer Revealed by Targeted Sequencing. Journal of Urologic Oncology. 2026;24(2):101-108. doi:10.22465/juo.255000700035
BibTeX
@article{Jeong2026,
author = {Jeong, Seung-Hwan and Han, Jang Hee and Yuk, Hyeong Dong and Jeong, Chang Wook and Ku, Ja Hyeon and Kwak, Cheol},
title = {Frequent Genetic Alterations in Metastatic Prostate Cancer Revealed by Targeted Sequencing},
journal = {Journal of Urologic Oncology},
year = {2026},
volume = {24},
number = {2},
pages = {101--108},
doi = {10.22465/juo.255000700035}
}
EUVIMED